D Durect Corp
D
Chiusa
0
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
Massimo
Dipendenti | 13 |
|---|
Raccomandazioni | Neutrale |
|---|---|
Previsioni per 12 mesi | +30.89% upside |
Capitalizzazione di Mercato | 51M |
|---|---|
Apertura precedente | 0 |
Chiusura precedente | 0 |
Durect Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Durect Corp Previsione
Obiettivo di Prezzo
By TipRanks
30.89% in crescita
Previsioni per 12 mesi
Media 2.5 USD 30.89%
Alto 2.5 USD
Basso 2.5 USD
Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Durect Corp - Dist negli ultimi 3 mesi.
Notizie finanziarie
$
Chi Siamo Durect Corp
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
